BLAINJECTIONINJECTABLE
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
AVSOLA (infliximab-axxq) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2019.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVSOLA is an infliximab biosimilar (infliximab-axxq) developed by Amgen, a monoclonal antibody that blocks tumor necrosis factor (TNF) to reduce inflammation. It is indicated for TNF-mediated inflammatory conditions and works by binding TNF receptors to suppress immune-driven inflammation. The product was approved in December 2019 as a biosimilar reference to Remicade.
$0.003BPart D
PeakAVSOLA is in peak commercialization phase with growing uptake; teams are focused on market penetration, competitive positioning, and maintaining biosimilar adoption momentum.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AVSOLA offers exposure to biosimilar market dynamics, payer negotiations, health economics, and digital/IT transformation within Amgen's biologics division. The 106 linked roles span R&D, data science, IT, and project management, indicating opportunities in portfolio analytics, market modeling, and operational excellence rather than late-stage clinical development.
Scientist
Worked on AVSOLA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.